Notice of Change to Key Dates for NIDA PAR-21-183, " Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)"
Notice Number:
NOT-DA-21-042

Key Dates

Release Date:

April 1, 2021

Related Announcements

PAR-21-183 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs applicants of a changes to the Key Dates for Funding Opportunity Announcement (FOA) PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)".  

 
The following Section of PAR-21-183 has been modified to reflect the changed dates:

Currently Reads:

Part 1. Overview Information

Key Dates

Open Date (Earliest Submission Date):

August 8, 2021

Letter of Intent Due Date(s):

30 days prior to application due date

Application Due Dates

Review and Award Cycles

New

Renewal / Resubmission / Revision (as allowed)

AIDS

Scientific Merit Review

Advisory Council Review

Earliest Start Date

September 08, 2021

September 08, 2021

September 08, 2021

November 2021

January 2022

April 2022

January 10, 2022

January 10, 2022

January 17, 2022

March 2022

May 2022

July 2022

September 08, 2022

September 08, 2022

September 08, 2022

November 2022

January 2023

April 2023

January 10, 2023

January 10, 2023

January 10, 2023

March 2023

May 2023

July 2023

September 08, 2023

September 08, 2023

September 08, 2023

November 2023

January 2024

April 2024

January 10, 2024

January 10, 2024

January 10, 2024

March 2024

May 2024

July 2024

Expiration Date:

January 11, 2024

Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Key Dates

Open Date (Earliest Submission Date):

July 4, 2021

Letter of Intent Due Date(s):

30 days prior to application due date  

Application Due Dates

Review and Award Cycles

New

Renewal / Resubmission / Revision (as allowed)

AIDS

Scientific Merit Review

Advisory Council Review

Earliest Start Date

August 4, 2021

August 4, 2021

August 4, 2021

November 2021

January 2022

April 2022

December 6, 2021

December 6, 2021

December 6, 2021

March 2022

May 2022

July 2022

August 4, 2022

August 4, 2022

August 4, 2022

November 2022

January 2023

April 2023

December 6, 2022

December 6, 2022

December 6, 2022

March 2023

May 2023

July 2023

August 4, 2023

August 4 2023

August 4, 2023

November 2023

January 2024

April 2024

December 6, 2023

December 6, 2023

December 6, 2023

March 2024

May 2024

July 2024

Expiration Date:

December 7, 2023

All other aspects of this FOA remain the same.  

Inquiries

Please direct all inquiries to:

Will M. Aklin, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5909
Email: aklinwm@nida.nih.gov

Kevin Walton, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5980
Email: kevin.walton@nih.go


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices